PDA Aseptic Manufacturing Excellence Conference 2025

Agenda

Monday, 13 October

AEDT Daylight Time (UTC +11:00)

08:00 – 08:45	Registration		
	Opening Plenary – Advancing Excellence in Aseptic Manufacture		
08:45 – 10:30		Welcome & Opening Remarks	
	08:45 - 08:55	 Justine D. Mann MBA, BSc, Chief Executive Officer, CBE Pure Solutions, President, PDA Australia Chapter 	
		Adoption of PIC/S PE009-17	
	08:55 – 09:25	 Matt Davis , Director, Inspections Section - Manufacturing Quality Branch, Therapeutic Goods Administration 	
		'Designing the State of Control' within the Contamination Control Strategy (CCS)	
	09:25 – 09:55	Tracy Moore , CEO, TM Pharma Group	
	09:55 – 10:30	Panel Discussion and Q&A	
10:30 – 11:10	Coffee Break		
	Session 1- Innov	vative Tools & Processes to Assure Sterility and Quality	
	11:10 – 11:15	Welcome Remarks	
11:10 – 12:35		Mylinh La PhD, Senior Laboratory Manager, CSIRO	
	11:15 – 11:40	Risk Based Approach for Design of Environmental Monitoring Programmes	
		 Kelly Waldron PhD, Business Unit Manager, Quality and Manufacturing Science Consulting, ValSource, Inc. 	
	11:40 – 12:05	Rapid Micro - Real-world challenges – and solutions – for the use of biofluorescent particle counters in Grade A aseptic filling applications	
		Brent N. Lieffers , Senior Director, Innovation Advocacy, Cytiva	
	12:05 – 12:20	Q&A	
	Product Demo b	by CAI	
40.00 40.05	12:20 – 12:35	Bridging the Gap from Project Mode to Sustained Operations	
12:20 – 12:35		• Lewis O'Brien , Country Manager-Australia & New Zealand, CAI	

	Session 2- Susta	aining & Maintaining Quality in Aseptic Manufacture
		Welcome Remarks
	13:35 – 13:40	• Micheal Schafferius , Application Specialist for Filtration and Quality, <i>Sartorius Stedim Biotech Australia</i>
		Developing a CCS (Contamination Control Strategy) for ATMP Cleanrooms
	13:40 – 14:05	James N. Polarine MA, Principal Consultant, STERIS
13:35 – 15:10	14:05 – 14:30	Sterility Assurance – Recent PDA publications to guide alignment with PIC/S Annex 1 Implementation • Bruce Loxley, Science Advisory Board member 2022-2028, PDA
		Navigating Quality and Compliance in a Biologics CDMO
	14:30 – 14:55	Melissa El Khouri , Head of Quality, BioCina Adelaide
	14:55 – 15:10	Q&A
15:10 – 15:50	Coffee Break	
	Session 3 - Con	current A: Case Studies in Quality and Compliance Across Aseptic Manufacturing
		Welcome Remarks
	15:50 – 15:55	Nadia Seidel , Site Operational Excellence Lead, Pfizer
		Challenges and Opportunities in Radiopharmaceutical Manufacturing
	15:55 – 16:20	Robert Raposio Ph.D., MMgt, Process Performance Manager, ANSTO Nuclear Medicine
45.50 47.40		Case Study - Operational Readiness- A Practical Approach
15:50 – 17:10	16:20 – 16:35	Christopher Cassidy , Operational Readiness Director, Pfizer
		Case Study - Risk Based Qualification of Facilities in Practice
	16:35 – 16:50	Samuel O'Callaghan , Managing Director - Australia & New Zealand, PSC Biotech
	16:50 – 17:05	Q&A
	17:05 – 17:10	Closing Remarks
	Session 3 - Con	current B: GMP Compliance and Quality Assurance in Veterinary Sterile Products
		Welcome Remarks
	15:50 – 15:55	• Justine D. Mann MBA, BSc, Chief Executive Officer, CBE Pure Solutions, <i>President, PDA Australia Chapter</i>
		GMP Changes
	15:55 – 16:20	• Malcom Hammond, Director, Manufacturing Quality and Licensing & Assurance, Australian Pesticides and Veterinary Medicines Authority (APVMA)
		Aseptic Manufacture & the APVMA Code: Meeting Today's Standards, Shaping Tomorrow's Compliance
15:50 – 17:25	16:20 – 16:45	Louise White , APVMA Auditor, Director and Consultant, SeerPharma Pty Ltd

	QRM Basics
16:45 – 17:10	 Kelly Waldron PhD, Business Unit Manager, Quality and Manufacturing Science Consulting, ValSource, Inc.
17:10 – 17:25	Q&A
	Closing Remarks
17:25 – 17:30	• Justine D. Mann MBA, BSc, Chief Executive Officer, CBE Pure Solutions, <i>President, PDA Australia Chapter</i>

17:10 – 19:10 **Networking Reception**

Tuesday, 14 October

AEDT Daylight Time (UTC +11:00)

07:30 – 08:45	Registration		
	Breakfast Session (Part 1)		
07:45 – 08:45		How to Use Lifecycle Risk Assessments to Improve Quality and Operational Processes	
	07:45 – 08:45	 Kelly Waldron PhD, Business Unit Manager, Quality and Manufacturing Science Consulting, ValSource, Inc. 	
08:45 – 09:00	Break		
09:00 – 09:15	Breakfast Session (Part 2)		
		Welcome to Day 2 - updates from the PDA Australia Chapter and Global PDA Network	
	09:00 – 09:15	• Justine D. Mann MBA, BSc, Chief Executive Officer, CBE Pure Solutions, <i>President, PDA Australia Chapter</i>	
		Sadman Bhuiyan , Project Manager, Scientist and Educator, INOVIQ Ltd.	
	Session 4- Steril	le Container Innovations: Meeting Annex 1 Expectations with Confidence	
		Welcome Remarks	
	09:15 – 09:20	Sadman Bhuiyan , Project Manager, Scientist and Educator, INOVIQ Ltd.	
09:15 – 10:25	09:20 – 09:45	Implementation of Annex 1 by Primary Packaging Suppliers: A Case Study for Improved Compliance via Advanced Particle Control and Reduced Interventions	
		Colleen O'Brien MS, Strategy and Technical Affairs, Gerresheimer	
	09:45 – 10:10	A Practical Road Map for Compliance to the Container Closure Requirements in the EU GMP Annex 1	
		Derek I Duncan PhD, Director Product Lines, LIGHTHOUSE Instruments	
	10:10 – 10:25	Panel Discussion and Q&A	

Welcome Remarks

	11:00 – 11:05	Jo Sherriff , Engineering Compliance Manager, SeerPharma Pty. Ltd.
		Cleaning Classified Rooms to meet EU Annex 1 requirements
	11:05 – 11:30	James N. Polarine MA, Principal Consultant, STERIS
11:00 – 12:35	11:30 – 11:55	GMP Myth Busting
		Brent N. Lieffers , Senior Director, Innovation Advocacy, Cytiva
		Aseptic Processing – Emerging expectations or a paradigm shift?
	11:55 – 12:20	Bruce Loxley , Science Advisory Board member 2022-2028, PDA
	12:20 – 12:35	Panel Discussion and Q&A
12:35 – 13:35	Lunch Break	
	Session 6- QC Ir	nnovation Spotlight: Case Studies in Advanced Testing for Sterility Assurance
	13:35 – 13:40	• Craig Stephens , Global Head of Quality Control Operations, CSL
		Case Study - Optimisation of Mycoplasma Testing using BioFire
	13:40 – 13:55	Melissa Damino , Director of Quality Control, Tullamarine, CSL Seqirus
13:35 – 14:50	13:55 – 14:10	Case Study - rFC Endotoxin Testing
		Robyn Hofer , Operations Manager, CBE Pure Solutions
		Case Study - Implementation of Automated EM Plate Reader
	14:10 – 14:25	Mark Gracie , LTS Manager, Pfizer
	14:25 – 14:50	Q&A
14:50 – 15:30	Coffee Break	
	Closing Plenary	- Annex 1 Hot Topics: Paradigm Shifts and GMPs for the 21st Century
	45.00 45.05	Welcome Remarks
	15:30 – 15:35	Lisa Bennett MSc, Director, LB Consulting Australia Pty Ltd
		PUPSIT - risk considerations and compliance
	15:35 – 16:00	• Matt Davis , Director, Inspections Section - Manufacturing Quality Branch, <i>Therapeutic Goods Administration</i>
		Introduction to the Panel Discussion
15:30 – 17:10	16:00 – 16:10	Lisa Bennett MSc, Director, LB Consulting Australia Pty Ltd
		Expert Panel Discussion and Q&A
		Tracy Moore , CEO, TM Pharma Group
		• Matt Davis , Director, Inspections Section - Manufacturing Quality Branch, <i>Therapeutic Goods Administration</i>

16:10 - 17:00

- Brent N. Lieffers , Senior Director, Innovation Advocacy, Cytiva
- James N. Polarine MA, Principal Consultant, STERIS
- **Malcom Hammond**, Director, Manufacturing Quality and Licensing & Assurance, *Australian Pesticides and Veterinary Medicines Authority (APVMA)*

Closing Remarks

17:00 - 17:10

Justine D. Mann MBA, BSc, Chief Executive Officer, CBE Pure Solutions, President, PDA Australia Chapter